FDA Vaccine Chief Resigns, Citing Concerns Over Kennedy's Stance on Vaccines; BIO Statement

The Food and Drug Administration's top vaccine official, Dr. Peter Marks, has resigned under pressure, directly criticizing Health Secretary Robert F. Kennedy Jr.'s approach to vaccine policy in his departure.

 

In his resignation letter to Acting FDA Commissioner Sara Brenner, Marks wrote: "It has become clear that truth and transparency are not desired by the secretary, but rather he wishes subservient confirmation of his misinformation and lies." Marks was reportedly given the option to resign or be fired during a meeting at the Department of Health and Human Services on Friday.

 

In a subsequent interview, Marks reinforced his concerns, stating: "This man doesn't care about the truth. He cares about what is making him followers."

 

John F. Crowley, president and CEO of the Biotechnology Innovation Organization (BIO), praised Marks' tenure in a statement following the announcement: "Under the extraordinary leadership of Dr. Peter Marks, the FDA shepherded in a new era of scientific breakthroughs -- from new vaccines to curative cell and gene therapies that have strengthened and saved the lives of millions of patients and families."

 

Crowley expressed concern about potential ramifications for healthcare innovation, noting: "We are deeply concerned that the loss of experienced leadership at the FDA will erode scientific standards and broadly impact the development of new, transformative therapies to fight diseases for the American people."

 

BIO emphasized its commitment to working with the new Commissioner and administration while stressing the importance of upholding scientific expertise and high standards at health institutions.


August 6, 2026
From breakthrough therapeutics to next-generation medical technologies, tomorrow's innovators take the stage at the Georgia Life Sciences Summit. Sponsored by Johnson & Johnson, the Startup Showcase will highlight eight of Georgia's most promising early-stage life sciences companies as they present their innovations during the Summit Luncheon on August 26. These emerging companies are tackling some of healthcare's biggest challenges across therapeutics, diagnostics, AI, and medical technology, while demonstrating the depth of innovation taking place throughout Georgia's life sciences ecosystem. Meet the 2026 Startup Showcase Companies: Abundance Biopharma Corporation Athna Biotech Atomistic Insights NovAb Nytricx Oridivus TremeBio YoungHeartValve Following the presentations, each company will participate in a live investor Q&A featuring an exceptional panel of venture leaders: Emily Dinu, Numinous Capital John Gutierrez, Ascenta Capital Dr. Emma Heckenberg, Solas BioVentures Patrick Jordan, NovaQuest Capital Management Tim Opler, Stifel Whether you're an investor looking for the next breakthrough, a corporate leader seeking innovative partners, or simply interested in the future of life sciences, the Startup Showcase offers a front-row seat to the companies poised to shape what's next. Join us August 25–26 at the Georgia Life Sciences Summit and discover the next generation of innovators driving Georgia's life sciences economy.
July 24, 2026
July 24, 2026, Atlanta, GA - Georgia Life Sciences applauds Congressman Rich McCormick (R-GA) for introducing the Biotechnology Diplomacy Leadership Act , legislation designed to strengthen America's leadership in biotechnology by establishing a senior biotechnology leadership position within the U.S. Department of State. As biotechnology continues to drive breakthroughs in healthcare, agriculture, advanced manufacturing, and national security, the United States must remain a global leader in innovation while strengthening strategic partnerships with allies around the world. The proposed legislation recognizes biotechnology as a critical component of U.S. economic competitiveness and foreign policy and would help ensure that the federal government is well positioned to advance these priorities internationally. The legislation also reflects recommendations from the National Security Commission on Emerging Biotechnology , which called for a more coordinated national approach to advancing biotechnology and protecting U.S. leadership in this strategically important sector. "Georgia is home to one of the nation's fastest-growing life sciences ecosystems, and policies that strengthen America's global biotechnology leadership directly benefit innovators, researchers, manufacturers, and patients," said Maria Thacker Goethe, President & CEO of Georgia Life Sciences. "We appreciate Congressman McCormick's leadership in recognizing biotechnology as both an economic engine and a strategic national priority." Georgia Life Sciences looks forward to working with policymakers at both the federal and state levels to advance policies that foster innovation, strengthen the U.S. bioeconomy, and ensure America remains the global leader in biotechnology.
July 21, 2026
Georgia Life Sciences names Renee Martin, Ph.D., to lead its Teacher Training Initiative, advancing educator workforce development and Georgia's future life sciences talent pipeline.
MORE POSTS